Bay 3547926

Phase 1

Bayer

Bay 3547926 is one of 30 therapeutic programs targeting Hepatocellular Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hepatocellular CarcinomaRecruiting

Hepatocellular CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Hepsera

Doptelet

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Valemetostat

Bristol-Myers Squibb

Preclinical

1 8

Alcohol

Astellas

Preclinical

—9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

1 10

Targeted Therapy

FFudan University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 1Recruiting

Hepatocellular Carcinoma

NCT06764316

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)

Recruiting· Bayer logo

Bayer·Phase 1·NCT06764316·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bay 3547926. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bay 3547926. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Bayer

Bay 3547926

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News